IAVI and its partners are advancing a diverse porfolio of select preventive HIV vaccine candidates.
IAVI details its organizational strategic vision for the period 2011-2015 made.
Engage with IAVI on your social media networks.
IAVI partners with more than 50 academic, biotechnology, pharmaceutical and governmental institutions to develop AIDS vaccines, and to advocate for the HIV-prevention field.
IAVI is working with partners to ensure that once a preventive AIDS vaccine is developed, it will be available to those who need it most.
As researchers make significantprogress toward the development ofan AIDS vaccine, new modeling datahighlights its potentially striking impact.
This report details key activities in 2011 that support IAVI's mission to develop a safe, effective accessible, preventive HIV vaccine for use throughout the world.
The report of a child functionally cured of HIV stirred up the typically staid proceedings of the Conference on Retroviruses and Opportunistic Infections.
VAX is the bulletin on AIDS vaccine research for you.